VectorialDATA
Stocks/ALC

ALC — Alcon Inc.

HealthcareEuropeSwitzerlandBlockchain certified

Price when we picked it (Jul 23, 2026)

$66.40

Target: $87.00 (+31%)

P/E Ratio

39.8

P/E Forward

16.7

Dividend

0.53%

Market Cap

$32.8B

EPS

$1.67

Consensus

Buy

What they do

Alcon (NYSE and Swiss exchange SIX: ALC) is the world's #1 company fully dedicated to eye care. It was born in Fort Worth, Texas, in 1945 (from a two-partner pharmacy: Alexander and Conner), belonged to Nestlé and then Novartis, and became an independent public company in April 2019. It has two businesses:

**

  • Surgery (~54% of sales)** — the heart of the company:
  • Cataract surgery equipment: the machines (phacoemulsification systems; the new UNITY platform) a surgeon uses to remove the lens clouded by the cataract.
  • Intraocular lenses: the artificial lens implanted in that eye. Its stars are PanOptix and PanOptix Pro (they correct both near and far vision) and Vivity.
  • Plus equipment for retina and refractive surgery.

**

  • Vision (~46% of sales)** — the consumer business:
  • Contact lenses: Precision1, Total30, Dailies.
  • Eye health: dry-eye drops Systane (market leader) and Tryptyr, a new prescription for dry eye.

Why it's a quality business: everyone's eyes age — cataracts are practically inevitable with age — the world performs more than 20 million cataract surgeries a year, and between them Alcon and Johnson & Johnson control ~50% of the equipment market for that surgery. It's specialized medical equipment where the surgeon trusts the brand and doesn't switch lightly.

Leadership: CEO David J. Endicott (since it became independent in 2019). HQ in Geneva, Switzerland, with a large operating center in Fort Worth, Texas. ~25,600 employees.

Why we like it

ALC at $66.40 is buying the world leader in eye care after a sharp drop — from ~$92 to ~$66 — whose causes are already behind it. Concrete reasons:

  • The valuation reset and the 'expensive P/E' is a mirage. At ~40 times accounting profit it looks expensive, but that number is inflated by a charge that isn't real money: the amortization of old acquisitions (~$696 million a year, a legacy of when it was split off from Novartis). On its true earnings ('core' profit of $3.07 per share, growing 10-13%) it trades at ~17 times — the cheapest it's been since it went public in 2019.
  • The bad news has already passed. The two blows that sank the stock — the mid-2025 target cut and the failed STAAR acquisition in January 2026 — are already in the past. The drop was driven by headlines, not because the business stopped working.
  • The business never broke. In Q1 2026 (reported May 6) sales grew +10% to $2.7 billion, adjusted profit +16%, and the company raised its profit-growth target for the year to +10-13%. That is not a company in trouble.
  • A nearly guaranteed demographic tailwind. The population over 60 will double by 2050, and cataracts come with age. Demand for surgeries and lenses only rises over time.
  • A wave of new products. Right now it's launching its UNITY platform, PanOptix Pro, the Tryptyr drop, and Valeda (for a retina disease) — several levers to beat already-lowered expectations. 'Buy' rating, average target ~$87 (~+31% from $66.40). It reports on August 10.

Key Risk

Risks:

  • Weaker cataract surgeries — the #1: that's exactly what triggered the 2025 target cut, and surgery is 54% of sales; if operation volumes don't recover, the thesis gets delayed.
  • Competition: Alcon and Johnson & Johnson split ~50% of the cataract market, but in contact lenses it's losing ground to CooperVision and J&J, and in surgery it competes with Bausch+Lomb and Zeiss.
  • U.S. tariffs: even though Alcon already lowered its assumption to 10%, it's still a live cost in 2026.
  • Currency exchange: it's a Swiss company that reports in dollars; currency swings move its numbers (in Q1 there were 4 points of difference between the 'real' growth and the reported growth).
  • Launch execution: the thesis rests on UNITY, PanOptix Pro, Tryptyr, and Valeda taking off; if they're delayed, the ghost of the target cut returns. And the dividend (~0.5%) is so small that it offers almost no cushion if the stock falls.

This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.

Vectorial Data picked ALC on Jul 23, 2026 at $66.40.

Full Research

Alcon (ALC) — Full Research

Price: $66.40 | P/E TTM: ~40x (accounting) / ~17x (core) | Div Yield: ~0.5% | Market Cap: ~$32.8 billion USD


What is Alcon?

The world's #1 company fully dedicated to eye care. Founded in Fort Worth, Texas, in 1945 (from the pharmacy of Alexander and Conner). It passed through Nestlé and Novartis, and became an independent public company in April 2019. HQ today in Geneva, Switzerland; it trades in New York (NYSE) and on the Swiss exchange (SIX). CEO David J. Endicott (since the 2019 spin-off). ~25,600 employees.

The 2 businesses (Q1 2026)

Segment% of salesWhat it isQ1 2026 sales
Surgery~54%Cataract surgery equipment (UNITY), intraocular lenses (PanOptix, Vivity), retina, refractive$1.46 billion (+10%)
Vision (Vision Care)~46%Contact lenses (Precision1, Total30, Dailies) + eye health (Systane, Tryptyr)$1.23 billion (+9%)

Latest quarter (Q1 2026, reported May 6, 2026)

MetricQ1 2026
Revenue$2.7 billion (+10% reported / +6% in constant currency)
Core EPS (adjusted)$0.85 (+16%), beat expectations
2026 guidanceSales +5-7%; core profit raised to +10-13%

FY2025: revenue ~$10.4 billion; core profit per share $3.07. Next report: ~August 10, 2026 (consensus ~$2.76 billion).

Why it fell from ~$92 to ~$66

It wasn't a single blow, but a series of disappointments over a year:

  • Target cut in mid-2025: it lowered its sales target for the year (to +4-5% from +6-7%) because of weaker cataract surgeries, some loss of share, and U.S. tariffs. The stock fell ~11-12% that day; several firms downgraded it.
  • The STAAR Surgical acquisition fell through: in August 2025 Alcon agreed to buy STAAR (implantable lenses to correct vision) for ~$28-30.75 per share, but STAAR's shareholders rejected it on January 6, 2026 and Alcon canceled the deal. It took away an expected growth leg.
  • BofA downgraded it to 'Underperform' after the deal's failure, with a price target of $75.

The result: the multiple compressed even though revenue kept growing at a double-digit pace.

The key valuation point: the 'expensive P/E' is a mirage

The ~40 accounting P/E is scary, but it's inflated by ~$696 million a year of intangible amortization — an accounting charge that isn't a cash outflow, a legacy of old acquisitions and the split from Novartis. If you look at the true earnings (core profit of $3.07 per share, growing 10-13%), the P/E drops to ~17 times: the cheapest it's been since 2019.

Anchor Fact

The world performs more than 20 million cataract surgeries every year, and between them Alcon and Johnson & Johnson make close to half the equipment and lenses used in them — meaning Alcon's technology is in the operating room of roughly ~10 million operations that give people their sight back each year. And because cataracts come with age, and the population over 60 will double by 2050, the demand is one of the most predictable in all of medicine.

Top 5 Risks

  • Weak cataract surgeries — it's what caused the 2025 cut; surgery is 54% of sales
  • Competition — Cooper/J&J in contact lenses; Bausch+Lomb/Zeiss in surgery
  • U.S. tariffs — a live cost in 2026 even at the assumed 10%
  • Currency exchange — a Swiss company that reports in dollars
  • Launch execution — UNITY, PanOptix Pro, Tryptyr, Valeda must take off; the dividend (~0.5%) gives little cushion

What Wall Street analysts expect

  • Rating: Buy / Overweight (~22 Buy / 3 Hold / 1 Sell)
  • Average target: ~$87 (~+31% from $66.40); range $66-$107

Thesis in one line

The world leader in eye care, on sale after two scares already behind it: the business is growing double-digit, the real valuation is ~17x, and the demographics of aging guarantee it customers for decades.

Research date: Jul 23, 2026 | Next review: Jan 2027

This is not financial advice.

More picks in Healthcare

See all Healthcare picks →

More picks from Switzerland

See all picks from Switzerland →
Researched: Jul 23, 2026Updated: Jul 23, 2026Next review: Jan 23, 2027

This is not financial advice. Consult a certified financial advisor.

The author may hold positions in the securities discussed.

Past performance does not guarantee future results.